Posted by Michael Wonder on 24 Oct 2023
Sumitomo Pharma announces authorisation in Canada of Orogvyx (relugolix) for the treatment of men with advanced prostate cancer
23 October 2023 - Orgovyx is the first and only oral gonadotropin-releasing hormone receptor antagonist approved for advanced prostate cancer in Canada.
Sumitomo Pharma Canada announced today that Health Canada has approved Orgovyx (relugolix), an oral gonadotropin-releasing hormone receptor antagonist, for the treatment of men with advanced prostate cancer.
